Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share data across its dermatologic portfolio of gene expression profile (GEP) tests via oral and electronic poster presentations at the 2024 AAD Annual Meeting, taking place March 8-12 in San Diego. “Our presentations at the 2024 AAD Annual Meeting add to the growing body of evidence supporting the use of our tests in guidi ...